Clinical Data Parsortix study shows promise for ADC target detection PharmaTimesResearchers highlight minimally invasive monitoring potentialOncologyRead full story pharminent August 3, 2026 (Last updated: August 3, 2026) PharmaTimes Researchers highlight minimally invasive monitoring potential Oncology Read full story Post navigation Previous: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular TrialNext: Curium strikes $8bn deal to buy radiopharma rival Lantheus Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
